NCT04161781View on ClinicalTrials.gov

A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer

CompletedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

November 12, 2019

Primary Completion Date

March 6, 2024

Study Completion Date

March 6, 2024

Conditions
Esophagogastric CancerEsophagus CancerEsophageal CancerGastric CancerGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaGastroesophageal Junction Squamous Cell Carcinoma
Interventions
DRUG

18F-BMS-986229 Injection

Single injection prior to scan

DRUG

IV 18F-BMS-986229

370 MBq administered intravenously prior to scan

DIAGNOSTIC_TEST

PET/CT Scan

Whole-body PET/CT (80 mA)

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT04161781 - A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer | Biotech Hunter | Biotech Hunter